rubitecan has been researched along with Adenocarcinoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balan, KV; Han, Z; Hu, X; Pantazis, P; Ramos-DeSimone, N; Wyche, JH | 1 |
| Berlin, J; Caillouette, C; Chakravarthy, B; Choy, H; Daniel Beauchamp, R; Lockhart, AC; Merchant, N; Rothenberg, M; Scott Pearson, A; Shyr, Y; Tedesco, KL; Wyman, K | 1 |
| Berlin, JD | 1 |
| Antonakis, PT; Golematis, BX; Konstadoulakis, MM; Manouras, AP; Mylonaki, DB; Stathopoulos, GP; Tsibloulis, BG | 1 |
2 trial(s) available for rubitecan and Adenocarcinoma
| Article | Year |
|---|---|
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Administration, Oral; Aged; Camptothecin; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage | 2005 |
A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies | 2001 |
2 other study(ies) available for rubitecan and Adenocarcinoma
| Article | Year |
|---|---|
Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Transformation, Neoplastic; Clone Cells; Female; Flow Cytometry; Genes, bcl-2; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 2003 |
Current and future strategies for treating metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Management; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2004 |